Cardiovascular Regenerative Medicine, Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA.
Ann N Y Acad Sci. 2010 Nov;1211:113-26. doi: 10.1111/j.1749-6632.2010.05814.x.
Heart disease is the leading cause of death in the industrialized world. This is partially attributed to the inability of cardiomyocytes to divide in a significant manner, and therefore the heart responds to injury through scar formation. One of the challenges of modern medicine is to develop novel therapeutic strategies to facilitate regeneration of cardiac muscle in the diseased heart. Numerous methods have been studied and a wide variety of cell types have been considered. To date, bone marrow stem cells, endogenous populations of cardiac stem cells, embryonic stem cells, and induced pluripotent stem cells have been investigated for their ability to regenerate infarcted myocardium, although stem cell transplantation has produced ambiguous results in human clinical trials. Several studies support another approach that seems very appealing: enhancing the limited endogenous regenerative capacity of the heart. The recent advances in stem cell and regenerative biology are giving rise to the view that cardiac regeneration, although not quite ready for clinical treatment, may translate into therapeutic reality in the not too distant future.
心脏病是工业化世界的主要死因。这部分归因于心肌细胞不能以显著的方式分裂,因此心脏通过疤痕形成来应对损伤。现代医学的挑战之一是开发新的治疗策略,以促进患病心脏中心肌的再生。已经研究了许多方法,并考虑了各种各样的细胞类型。迄今为止,骨髓干细胞、内源性心肌干细胞、胚胎干细胞和诱导多能干细胞已经被研究用于其再生梗死心肌的能力,尽管干细胞移植在人类临床试验中产生了不确定的结果。一些研究支持另一种方法,这种方法似乎非常有吸引力:增强心脏有限的内源性再生能力。干细胞和再生生物学的最新进展使得人们认为,尽管心脏再生还不完全适合临床治疗,但在不久的将来可能会转化为治疗现实。